Here’s What UBS Thinks About Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE:LLY) is one of the Best Unstoppable Growth Stocks to Buy Right Now. On January 7, Michael Yee from UBS initiated coverage of Eli Lilly and Company (NYSE:LLY) with a Buy rating and raised the price target from $1,080 to $1,250. The analyst noted the company’s leadership in the obesity treatment market as one of the key factors behind his bullish sentiment. The firm highlighted that the company’s performance in 2026 would be driven by the anticipated approval of obesity drug Orf ...